PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042570
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042570
Biopreservation Market size was valued at US$ 4,702.67 Million in 2025, expanding at a CAGR of 29.81% from 2026 to 2033.
Biopreservation is defined as the procedure through which living cells, tissues, organs, and other biological substances are preserved under certain conditions, such that they can be used again at some point in the future. Biopreservation uses low-temperature methods, cryogenics, and preservatives to maintain biological samples. It is widely used in hospitals and research centers, supporting regenerative medicine and pharmaceutical studies by preserving sample structure and molecular stability.
The biopreservation field is supported by strong research and healthcare systems across major regions. In the USA, agencies like the NIH and the FDA encourage the growth of cellular therapies and provide proper safety and storage guidelines for biological samples. The CDC also encourages biobanking techniques for biomedical research. At an international level, WHO backs the standardization of biological preservation for use in health care projects. In Europe and Asia, governments have been setting up research institutes to develop better cryostorage facilities for advancing medical science.
Biopreservation Market- Market Dynamics
Rising demand for advanced therapies and regenerative medicine
Increased demand for sophisticated medical procedures and regenerative medicines is fueling the expansion of biopreservation due to the fact that such medical interventions require living cells, tissues, and genetic material to be preserved. In the United States, the National Institutes of Health (NIH) continues to fund large-scale research programs focused on cell and gene therapies, which require reliable preservation methods for safe handling and long-term use.
The U.S. Food and Drug Administration (FDA) also provides structured guidance for regenerative medicine products, encouraging strict storage and transport conditions for biological materials. In Europe, the European Medicines Agency has established frameworks to promote quality control systems in therapies using cells. This is being done in various countries, including Japan, where the promotion of regenerative medicine research is supported by the Ministry of Health, Labour and Welfare. These efforts by governments across the globe are resulting in increased requirements for preservation systems.
The Global Biopreservation Market is segmented on the basis of Product, Application, Biospecimen, Preservation Method, End User, and Region.
From a biospecimen perspective, cells and cell lines are expected to remain a key segment in the market because of their wide use in drug discovery, regenerative medicine, and therapeutic research. These materials require careful freezing and recovery conditions, which increases the need for advanced storage and handling systems. Companies such as PHC Holdings (PHCbi) have recently strengthened this area through improved ultra-low temperature freezer systems designed to maintain stable storage conditions for sensitive biological materials. On the same note, Sartorius AG has improved the tools used for supporting cell culture and preservation so as to provide help to laboratories in ensuring the quality of their cells during the process of research. On the other hand, Merck KGaA has also come into this area with the help of special cell media and preservation products.
In terms of preservation method, cryopreservation is positioned to contribute notably, as it supports long-term storage of cells, tissues, and genetic materials that support advanced therapy development. This helps in ensuring that biological specimens stay stable for longer periods by means of controlled cooling processes, and this is crucial in the field of regenerative medicine and cell therapy production. There have been many government-sponsored initiatives that have emphasized the significance of employing a dependable cryostorage system; these include initiatives by the U.S. NIH to fund cell and gene therapy research and initiatives by the EMA on advanced therapy medicinal products. Companies such as Thermo Fisher Scientific have recently strengthened this area through upgraded ultra-low temperature storage systems designed to maintain sample integrity for sensitive biological applications. These advancements show how cryopreservation continues to support reliable biological storage practices across research and healthcare systems globally.
Biopreservation Market- Geographical Insights
From a geographical perspective, the combination of North America and Europe represents considerable significance in biopreservation market because of their powerful infrastructure for research along with an increasing emphasis on regenerative medicine, cellular therapies, and long-term storage of biological samples. The NIH in North America is known for promoting research and biobanking initiatives related to regenerative medicines, whereas the FDA offers clear regulatory pathways in cell and gene therapy areas. Canada also contributes through national health research initiatives supporting tissue preservation and biobank expansion. In Europe, the European Medicines Agency (EMA) and European Commission funding programs guide biomedical research collaboration, while countries like Germany, the UK, and France support large-scale stem cell and biobanking initiatives. In addition to these activities, companies like Thermo Fisher Scientific and BioLife Solutions in North America and Sartorius and Merck KGaA in Europe offer sophisticated cryogenic storage solutions and cryopreservation media that are used for keeping biological materials stable in research and medical fields. All of these factors serve to further enhance the positions of both North America and Europe in the field of biological material preservation.
Spain Biopreservation Market- Country Insights
Spain is emerging as an important contributor in the biopreservation field due to its structured healthcare system and growing focus on biomedical research. The country's National Health System supports coordinated healthcare services, which helps in strengthening laboratory and hospital-based biological sample management. Spain's Ministry of Science and Innovation is also promoting research programs in biotechnology and regenerative medicine, encouraging the development of advanced storage and preservation technologies. The Carlos III Health Institute (Instituto de Salud Carlos III) plays a key role in funding biomedical research projects, including biobanking and disease-related studies. Also, Spain is involved in European Union research programs that have been funded by the European Commission, making collaboration within scientific programs and infrastructure building easier. Such initiatives that have received government support are also leading to better cryogenic storage and biobanking in hospitals, universities, and research institutes.
The business environment in biopreservation reflects strong involvement of multiple solution providers across regions. Firms such as BioLife Solutions, PHC Holdings, Cryoport, and Sartorius focus on improving preservation quality and reliability for sensitive biological materials. These companies mainly serve research institutes, hospitals, and biotechnology firms, where sample stability is essential. They use various sales channels, including direct supply, distributors, and specialized partnerships. Continuous innovation in cryogenic systems and storage automation is helping companies maintain strong positions in research-driven applications across healthcare and life sciences sectors. For example, Cryoport introduced more partners in 2025 in their temperature-controlled logistics network to further increase its capacity in aiding cell therapy logistics, while PHC Holdings upgraded its ultra-low temperature freezer systems to maximize efficiency and ensure better safety. The companies of Merck KGaA and BioCision are investing in sophisticated biological sample preservation media and instruments. All these efforts demonstrate an upward trend toward greater reliability and increased storage accuracy and efficiency.
In March 2026, Azenta introduced upgraded automated biostorage and sample management systems aimed at improving large-scale biobanking efficiency and traceability in research facilities. Azenta's innovation enhances biobanking automation, improving sample tracking, operational efficiency, and reliability in large-scale research and storage facilities globally.
In January 2026, Thermo Fisher expanded its next-generation ultra-low temperature storage portfolio, strengthening its cryogenic and sample preservation capabilities for cell and gene therapy applications. Thermo Fisher's expansion enhances ultra-low temperature storage solutions, supporting advanced cryogenic preservation for cell and gene therapy research applications globally.